Avnalit 10 Capsule

Introduction

Avnalit is a prescription medication that contains the active ingredient Lenvatinib. It is available in capsule form and is used for the treatment of certain types of cancer.

Uses

Avnalit is primarily prescribed for the treatment of differentiated thyroid cancer (DTC) and unresectable hepatocellular carcinoma (HCC). It may be used when the cancer cannot be removed through surgery or has spread to other parts of the body.

Dosage and Administration

The dosage of Avnalit will depend on various factors, including the patient’s body weight, overall health, and the specific type of cancer being treated. Follow the instructions provided by your healthcare professional. The capsules should be swallowed whole with a glass of water, and can be taken with or without food. It is recommended to take Avnalit at the same time each day to maintain consistent blood levels of the medication.

Mechanism of Action

Lenvatinib, the active ingredient in Avnalit, is a type of targeted therapy known as a tyrosine kinase inhibitor. It works by blocking the action of specific proteins in cancer cells that promote tumor growth and blood vessel formation. By inhibiting these proteins, Avnalit helps to slow down or stop the growth and spread of cancer cells.

Side Effects

Common side effects may include fatigue, loss of appetite, high blood pressure, diarrhea, nausea, and weight loss. Report any side effects to your healthcare professional. In some cases, Avnalit may cause more serious side effects, such as severe bleeding, heart problems, or liver damage. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Avnalit may interact with other medications, including prescription drugs, over-the-counter medicines, and herbal supplements. Inform your healthcare professional about all the medications you are currently taking, including any changes in your medication regimen. Some medications may increase the risk of side effects or reduce the effectiveness of Avnalit. Your healthcare professional will be able to provide guidance on any potential drug interactions.

Precautions

Before starting treatment with Avnalit, inform your healthcare professional about any allergies, medical conditions, or medications you are currently taking. Avnalit may not be suitable for everyone, and your healthcare professional will assess whether it is the right treatment option for you. Follow all precautions provided by your healthcare professional, including avoiding certain foods, beverages, or activities that may interact with the medication.

Storage

Patient Tips

• Take Avnalit exactly as prescribed by your healthcare professional. Do not change the dosage or frequency of administration without consulting your healthcare professional.
• attend all scheduled appointments with your healthcare professional for regular check-ups and monitoring of your condition.
• If you experience any new or worsening symptoms while taking Avnalit, contact your healthcare professional immediately.
• Be aware of the potential side effects of Avnalit and report any changes or concerns to your healthcare professional.
• Follow all precautions provided by your healthcare professional, including any dietary or lifestyle modifications that may be necessary during treatment.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Kisplyx 10 mg hard capsules (Health Professionals SmPC) Available at:
• Lenvatinib (Drugs.com) [Accessed 4 Jun. 2024] (online) Available at:
• lenvatinib capsule (RX) [Accessed 9 Jun. 2024] (online) Available at:
• Lenvatinib (MedlinePlus) [Accessed 22 Jun. 2024] (online) Available at:
• Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. [Accessed 2 Jun. 2024] Available at: